November 7, 2017
Stockholm – November 7, 2017 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend Jefferies annual Healthcare Conference in London on November 16th.
Oncopeptides is a research and development stage pharmaceutical company developing drugs for the treatment of cancer. Since the founding of the company, the focus has primarily been on the development of the lead product candidate Ygalo®, an innovative, peptidase-potentiated alkylator intended for effective and focused treatment of hematological cancers, and in particular multiple myeloma.
Ygalo® has been used to treat late-stage RRMM patients in both phase I and phase II clinical studies with favorable results. Currently, Ygalo® is being studied in three clinical trials for the treatment of multiple myeloma. The current studies are O-12-M1, HORIZON and OCEAN. A fourth study, ANCHOR, will be initiated towards the end of 2017 to further investigate Ygalo® in multiple myeloma as part of combination therapies.
The current clinical study program is intended to demonstrate better results from treatment with Ygalo® compared to established alternative drugs for patients with late-stage multiple myeloma. Ygalo® could potentially provide physicians with a new treatment option for patients suffering from this serious disease.
Recent announcement around two clinical studies to be presented at ASH in December, include final data from the phase II- study O-12-M1 and interim data from the ongoing phase II-study HORIZON.
Ygalo® is a next generation alkylator compound that targets cancer cells through a mechanism called peptidase potentiation. In cell culture studies, traditional alkylators target cancer cells (which treats the disease) and bone marrow cells (which causes side effects) equally well. In contrast, Ygalo® targets the cancer cells 50x better than the bone-marrow cells.
Visit www.oncopeptides.se for more information.
For further information, please contact:
Rein Piir, Head of Investor Relations at Oncopeptides
This information was submitted for publication at 16.30 CET November 7, 2017